Cancer Research UK logo.
SearchDonate
  • Search

A trial looking at vistusertib and selumetinib for advanced cancer (TORCMEK)

Overview

Cancer types:

All cancer types, Breast cancer, Secondary cancers

Status:

Results

Phase:

Phase 1/2

Details

This trial looked at vistusertib and selumetinib for that had spread into the surrounding tissues or elsewhere in the body. Cancer that has spread is .

The trial was for people who didn’t have any options available to them.

It was open for people to join between 2015 and 2018. The team published some results in 2017 and reported some more results in 2022. Cancer Research UK supported this trial.

You pronounce selumetinib as sell-you-me-ti-nib.

Recruitment start: 8 June 2015

Recruitment end: 13 June 2018

How to join

Please note: In order to you will need to discuss it with your doctor, unless otherwise specified.

Chief investigators

Professor Peter Schmid

Supported by

Cancer Research UK

AstraZeneca

Experimental Cancer Medicine Centre (ECMC)

NIHR Clinical Research Network: Cancer

Queen Mary University of London

Other information

This is Cancer Research UK trial number CRUKDE/14/010.

Last reviewed: 03 Oct 2024

CRUK internal database number: 12210

Help and support